|Drug Name||GPCR-targeted Project 009|
G-protein coupled receptor family C group 5 member D (GPRC5D) is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation. A humanized T-cell redirecting bispecific antibody targeting both GPRC5D and CD3 antigen is being developed for the treatment of multiple myeloma. The antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells to result in the cross-linking of T cells and tumor cells, thereby inducing a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
|Target||G protein-coupled receptor 5D (GPRC5D); CD3|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||Antibody-dependent cell cytotoxicity|
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.